Beyondspring

Beyondspring Liabilities

The The Liabilities of Beyondspring (BYSI) as of Oct 10, 2026 is 49.92 M USD. In the previous year, The Liabilities was 48.60 M USD — a change of 2.72% (higher).

Liabilities

49.92 MUSD

YoY

2.72%

Last updated:

In 2025, Beyondspring's total liabilities amounted to 49.92 M USD, a 2.72% difference from the 48.60 M USD total liabilities in the previous year.

The Beyondspring Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
16.45 M USD
Jan 1, 2019
13.42 M USD
Jan 1, 2020
25.22 M USD
Jan 1, 2021
60.73 M USD
Jan 1, 2022
49.23 M USD
Jan 1, 2023
48.27 M USD
Jan 1, 2024
48.60 M USD
Jan 1, 2025
49.92 M USD
The Beyondspring Liabilities history
YEARLiabilitiesYoY
49.92 MUSD+2.72%
48.60 MUSD+0.69%
48.27 MUSD-1.95%
49.23 MUSD-18.93%
60.73 MUSD+140.81%
25.22 MUSD+87.85%
13.42 MUSD-18.37%
16.45 MUSD+243.18%
4.79 MUSD+83.67%
2.61 MUSD+98.86%
1.31 MUSD-87.58%
10.57 MUSD—
Access this data via the Eulerpool API

Beyondspring Stock analysis

What does Beyondspring do? Beyondspring Inc is a globally operating biopharmaceutical company dedicated to the development of innovative cancer drugs. The company was founded in 2014 in New York City and today Beyondspring is based in New York and Shanghai. The founding of Beyondspring aimed to bring innovative cancer therapies to market that provide better treatment outcomes for patients. The company particularly focuses on a combination of proven therapeutic approaches and innovative technology, aiming to take a leading role in the oncology industry. Beyondspring focuses on the development of highly effective cancer therapies based on two platform technologies: protein engineering and immuno-oncology. The company is searching for substances that can strengthen the body's immune system and attack cancer cells. At the core of its business operations is the product Plinabulin. This is a novel cyclic peptide drug that is capable of activating the immune system and destroying cancer cells. The drug has been tested in multiple clinical trials and has shown promising results, particularly in breast cancer and lung cancer. In addition to product development, Beyondspring is also involved in the market development and commercialization of cancer drugs. The company works closely with hospitals, doctors, and other healthcare stakeholders to promote the use of Plinabulin and improve patient care. Beyondspring specializes in various types of cancer, such as lung cancer, breast cancer, and leukemia, where Plinabulin can be used. The company strives to constantly expand its product portfolio to explore additional indications. Beyondspring's business model relies on close collaboration with industry partners and the establishment of a global network. The company collaborates with leading research institutions and universities and continuously invests in the development of innovative technologies. The goal of Beyondspring is to provide cancer patients worldwide with access to innovative and highly effective treatment options. To achieve this, the company collaborates with regulatory authorities to expedite the approval of new drugs. Overall, Beyondspring is characterized by a highly dynamic and future-oriented business model. With its focus on innovative cancer therapies and the continuous expansion of its portfolio, the company has already established a strong position in the industry. In the future, Beyondspring will continue to expand its global presence and broaden its product range to provide cancer patients with the best possible treatment outcomes. Beyondspring is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Beyondspring's Liabilities

Beyondspring's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Beyondspring's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Beyondspring's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Beyondspring's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Beyondspring’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Beyondspring stock

The Liabilities of Beyondspring is 49.92 M USD in 2025.

The Liabilities of Beyondspring changed from 48.60 M USD to 49.92 M USD, representing a 2.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Beyondspring since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Beyondspring historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Beyondspring

All Key Metrics — Beyondspring